title: Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.
abstract: Cocktails of monoclonal antibodies (MAbs) that target the surface glycoprotein (GP) of Ebola virus (EBOV) are effective in nonhuman primate models and have been used under emergency compassionate-treatment protocols in human patients. However, the amino acids that form the detailed binding epitopes for the MAbs in the ZMapp, ZMAb, and the related MB-003 cocktails have yet to be identified. Other binding properties that define how each MAb functionally interacts with GP—such as affinity, epitope conservation, and epitope accessibility—also remain largely unknown. To help define how each MAb interacts with GP, here we used comprehensive alanine-scanning mutagenesis (shotgun mutagenesis), neutralization escape, and whole virion binding to define each MAb's specific epitope, epitope accessibility, epitope conservation, and apparent affinity. Each of the six therapeutic MAbs binds nonidentical epitopes in the GP base, glycan cap, or mucin-like domain. Their apparent affinity, epitope complementarity, and epitope accessibility helps explain why MAbs 4G7 and 13C6 are more protective than 2G4 and 1H3. The mucin-like domain MAbs 6D8 and 13F6 bind with the strongest apparent affinity, helping to explain their effectiveness in vivo despite their inability to neutralize virus.
  
  
  OBJECTIVE
  Ebola virus disease (EVD) can be caused by four different filovirus family members, including Ebola virus (EBOV), which infected 10 times more people in western Africa over the last year than all previous EVD outbreaks combined, with a number of cases distributed across the globe by travelers. Cocktails of inhibitory monoclonal antibodies (MAbs), such as ZMAb, MB-003, and in particular ZMapp, have demonstrated in animal models some of the most significant therapeutic potential for treating EVD, and in 2014, 15 patients were treated with ZMapp or ZMAb under compassionate-use protocols. Here, we have defined the epitope features for the most important therapeutic MAbs against EBOV developed to date. Defining the epitopes and binding characteristics for these MAbs, as well as the commonly used reference MAb KZ52, helps explain their breadth of reactivity against different ebolavirus species, predict viral evasion against these MAbs, and design new cocktails of MAbs with improved complementarity.
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Edgar
authors: E
authors: Davidson
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Christopher
authors: C
authors: Bryan
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Rachel H
authors: RH
authors: Fong
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Trevor
authors: T
authors: Barnes
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Jennifer M
authors: JM
authors: Pfaff
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Manu
authors: M
authors: Mabila
authors: Integral Molecular, Philadelphia, Pennsylvania, USA.
authors: Joseph B
authors: JB
authors: Rucker
authors: Integral Molecular, Philadelphia, Pennsylvania, USA bdoranz@integralmolecular.com.
authors: Benjamin J
authors: BJ
authors: Doranz
mesh_terms: D000911:Antibodies, Monoclonal / Q000378:metabolism*; D029043:Ebolavirus / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000235:genetics; D005455:Fluorescent Antibody Technique; D006801:Humans; D016296:Mutagenesis; D009500:Neutralization Tests; D011485:Protein Binding; D014760:Viral Fusion Proteins / Q000378:metabolism*; D014771:Virion / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000939:Epitopes; D014760:Viral Fusion Proteins; C000594176:ZMapp